Influenza vaccination and humoral alloimmunity in solid organ transplant recipients. 2014

Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
Transplantation Center, University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Annual influenza vaccination is recommended in solid organ transplant (SOT) recipients. However, concerns have been raised about the impact of vaccination on antigraft alloimmunity. We evaluated the humoral alloimmune responses to influenza vaccination in a cohort of SOT recipients between October 2008 and December 2011. Anti-HLA antibodies were measured before and 4-8 weeks after influenza vaccination using a solid-phase assay. Overall, 169 SOT recipients were included (kidney = 136, lung = 26, liver = 3, and combined = 4). Five (2.9%) of 169 patients developed de novo anti-HLA antibodies after vaccination, including one patient who developed donor-specific antibodies (DSA) 8 months after vaccination. In patients with pre-existing anti-HLA antibodies, median MFI was not significantly different before and after vaccination (P = 0.73 for class I and P = 0.20 for class II anti-HLA antibodies) and no development of de novo DSA was observed. Five episodes of rejection (2.9%) were observed within 12 months after vaccination, and only one patient had de novo anti-HLA antibodies. The incidence of development of anti-HLA antibodies after influenza vaccination in our cohort of SOT recipients was very low. Our findings indicate that influenza vaccination is safe and does not trigger humoral alloimmune responses in SOT recipients.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human

Related Publications

Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
December 2012, Current opinion in organ transplantation,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
August 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
February 2012, The Annals of pharmacotherapy,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
March 2012, Pediatric transplantation,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
March 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
January 2020, Frontiers in immunology,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
December 2021, Clinical chemistry,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
February 2017, Human vaccines & immunotherapeutics,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
August 2018, Current opinion in infectious diseases,
Pieter Vermeiren, and Vincent Aubert, and Rocco Sugamele, and John-David Aubert, and Jean-Pierre Venetz, and Pascal Meylan, and Manuel Pascual, and Oriol Manuel
June 2020, Scientific reports,
Copied contents to your clipboard!